Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.
The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial.
It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 11, 25 | -1.20 Decreased by -275.00% | -1.07 Decreased by -11.89% |
| Nov 13, 24 | -0.86 Decreased by -68.63% | -0.74 Decreased by -16.22% |
| Aug 26, 24 | -0.60 Increased by +84.13% | -0.55 Decreased by -9.09% |
| May 13, 24 | -0.64 Increased by +73.11% | -0.61 Decreased by -4.92% |
| Mar 5, 24 | -0.32 | -0.49 Increased by +34.69% |
| Nov 13, 23 | -0.51 | -0.41 Decreased by -24.39% |
| Aug 28, 23 | -3.78 | -1.70 Decreased by -122.35% |
| May 31, 23 | -2.38 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -67.22 M Decreased by -111.81% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -49.02 M Decreased by -135.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -33.82 M Decreased by -79.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -32.09 M Decreased by -156.24% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -31.73 M Decreased by -126.57% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -20.84 M Decreased by -6.02% | Decreased by N/A% - |
| Jun 30, 23 | 0.00 Decreased by N/A% | -18.89 M Decreased by -939.92% | Decreased by N/A% - |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.53 M Decreased by -190.94% | Decreased by N/A% - |